INTRODUCTION: Pre-eclampsia affects ~5%-7% of pregnancies. Although improved obstetric care has significantly diminished its associated maternal mortality, it remains a leading cause of maternal morbidity and mortality in the world. Term pre-eclampsia accounts for 70% of all cases and a large proportion of maternal-fetal morbidity related to this condition. Unlike in preterm pre-eclampsia, the prediction and prevention of term pre-eclampsia remain unsolved. Previously proposed approaches are based on combined third-trimester screening and/or prophylactic drugs, but these policies are unlikely to be widely implementable in many world settings. Recent evidence shows that the soluble fms-like tyrosine kinase-1 (s-Flt-1) to placental growth factor (PlGF) ratio measured at 35-37 weeks' gestation predicts term pre-eclampsia with an 80% detection rate. Likewise, recent studies demonstrate that induction of labour beyond 37 weeks is safe and well accepted by women. We hypothesise that a single-step universal screening for term pre-eclampsia based on sFlt1/PlGF ratio at 35-37 weeks followed by planned delivery beyond 37 weeks reduces the prevalence of term pre-eclampsia without increasing the caesarean section rates or worsening the neonatal outcomes. METHODS AND ANALYSIS: We propose an open-label randomised clinical trial to evaluate the impact of a screening of term pre-eclampsia with the sFlt-1/PlGF ratio followed by planned delivery in asymptomatic nulliparous women at 35-37 weeks. Women will be assigned 1:1 to revealed (sFlt-1/PlGF known to clinicians) versus concealed (unknown) arms. A cut-off of >90th centile is used to define the high risk of subsequent pre-eclampsia and offer planned delivery from 37 weeks. The efficacy variables will be analysed and compared between groups primarily following an intention-to-treat approach, by ORs and their 95% CI. This value will be computed using a Generalised Linear Mixed Model for binary response (study group as fixed effect and the centre as intercept random effect). ETHICS AND DISSEMINATION: The study is conducted under the principles of Good Clinical Practice. This study was accepted by the Clinical Research Ethics Committee of Hospital Clinic Barcelona on 20 November 2020. Subsequent approval by individual ethical committees and competent authorities was granted. The study results will be published in peer-reviewed journals and disseminated at international conferences. TRIAL REGISTRATION NUMBER: NCT04766866.

BCNatal Fetal Medicine Research Center Hospital Clínic and Hospital Sant Joan de Déu University of Barcelona Barcelona Spain

Biochemistry Hospital Sant Pau Barcelona Spain

Centre Hospitalier Universitaire de Liège Liege Belgium

Centre of Postgraduate Medical Education Obstetrics and Gynecology and Perinatal Medicine Warsaw Poland

Hospital Clinic de Barcelona Barcelona Spain

Hospital del Mar Barcelona Spain

Hospital Germans Trias i Pujol Badalona Spain

Hospital Politécnico y Universitario La Fe Valencia Spain

IDIBAPS Barcelona Spain

Institute for the Care of Mother and Child 3rd Faculty of Medicine Charles University Prague Czech Republic

Obstetrician Son Llàtzer Hospital Palma de Mallorca Illes Balears Spain

Obstetrics and Gynecology Hospital de la Santa Creu i Sant Pau Barcelona Spain

Unidad Medicina Fetal Murcia IMIB Arrixaca Hospital Clínico Universitario Virgen de la Arrixaca Murcia Spain

See more in PubMed

Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130–7. 10.1053/j.semperi.2009.02.010 PubMed DOI

Say L, Chou D, Gemmill A, et al. . Global causes of maternal death: A WHO systematic analysis. Lancet Glob Health 2014;2:e323–33. 10.1016/S2214-109X(14)70227-X PubMed DOI

Gardosi J, Kady SM, McGeown P, et al. . Classification of Stillbirth by relevant condition at death (Recode): population based cohort study. BMJ 2005;331:1113–7. 10.1136/bmj.38629.587639.7C PubMed DOI PMC

Iams JD, Goldenberg RL, Mercer BM, et al. . The preterm prediction study: recurrence risk of spontaneous preterm birth. Am J Obstetri Gynecolo 1998;178:1035–40. 10.1016/S0002-9378(98)70544-7 PubMed DOI

Williams D. Long-term complications of preeclampsia. Semin Nephrol 2011;31:111–22. 10.1016/j.semnephrol.2010.10.010 PubMed DOI

Davis EF, Lazdam M, Lewandowski AJ, et al. . Cardiovascular risk factors in children and young adults born to preeclamptic pregnancies: a systematic review. Pediatrics 2012;129:e1552–61. 10.1542/peds.2011-3093 PubMed DOI

Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early-versus late-onset disease. Am J Obstet Gynecol 2013;209:544. 10.1016/j.ajog.2013.08.019 PubMed DOI

Weitzner O, Yagur Y, Weissbach T, et al. . Preeclampsia: risk factors and neonatal outcomes associated with early- versus late-onset diseases. J Matern Fetal Neonatal Med 2020;33:780–4. 10.1080/14767058.2018.1500551 PubMed DOI

Steegers EA, von Dadelszen P, Duvekot JJ, et al. . Pre-eclampsia. Lancet 2010;376:631–44. 10.1016/S0140-6736(10)60279-6 PubMed DOI

Kalafat E, Thilaganathan B. Cardiovascular origins of preeclampsia. Curr Opin Obstet Gynecol 2017;29:383–9. 10.1097/GCO.0000000000000419 PubMed DOI

Kornacki J, Wirstlein P, Wender-Ozegowska E. n.d. Markers of endothelial injury and dysfunction in early- and late-onset preeclampsia. Life;10:239. 10.3390/life10100239 PubMed DOI PMC

Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol 2013;209:544. 10.1016/j.ajog.2013.08.019 PubMed DOI

Rolnik DL, Wright D, Poon LC, et al. . Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017;377:613–22. 10.1056/NEJMoa1704559 PubMed DOI

Döbert M, Varouxaki AN, Mu AC, et al. . Pravastatin versus placebo in pregnancies at high risk of term preeclampsia. Circulation 2021;144:670–9. 10.1161/CIRCULATIONAHA.121.053963 PubMed DOI

Cluver C, Novikova N, Koopmans CM, et al. . Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term. Cochrane Database Syst Rev 2017;1:CD009273. 10.1002/14651858.CD009273.pub2 PubMed DOI PMC

Grobman WA, Rice MM, Reddy UM, et al. . Labor induction versus expectant management in low-risk nulliparous women. N Engl J Med 2018;379:513–23. 10.1056/NEJMoa1800566 PubMed DOI PMC

Middleton P, Shepherd E, Morris J, et al. . Induction of labour at or beyond 37 weeks' gestation. Cochrane Database Syst Rev 2020;7:CD004945. 10.1002/14651858.CD004945.pub5 Available: 10.1002/14651858.CD004945.pub5 PubMed DOI PMC

Crovetto F, Triunfo S, Crispi F, et al. . First-trimester screening with specific algorithms for early- and late-onset fetal growth restriction. Ultrasound Obstet Gynecol 2016;48:340–8. 10.1002/uog.15879 PubMed DOI

Gallo DM, Wright D, Casanova C, et al. . Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks’ gestation. Am J Obstet Gynecol 2016;214:619. 10.1016/j.ajog.2015.11.016 PubMed DOI

Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 2009;24:147–58. 10.1152/physiol.00043.2008 PubMed DOI

Karumanchi SA. Angiogenic factors in Preeclampsia: from diagnosis to therapy. Hypertension 2016;67:1072–9. 10.1161/HYPERTENSIONAHA.116.06421 PubMed DOI

Zeisler H, Llurba E, Chantraine F, et al. . Predictive value of the sFlt-1:Plgf ratio in women with suspected preeclampsia. N Engl J Med 2016;374:13–22. 10.1056/NEJMoa1414838 PubMed DOI

Chappell LC, Duckworth S, Seed PT, et al. . Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013;128:2121–31. 10.1161/CIRCULATIONAHA.113.003215 PubMed DOI

Rana S, Powe CE, Salahuddin S, et al. . Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911–9. 10.1161/CIRCULATIONAHA.111.054361 PubMed DOI PMC

Valiño N, Giunta G, Gallo DM, et al. . Biophysical and biochemical markers at 35-37 weeks’ gestation in the prediction of adverse perinatal outcome. Ultrasound Obstet Gynecol 2016;47:203–9. 10.1002/uog.15663 PubMed DOI

Döbert M, Wright A, Varouxaki AN, et al. . STATIN trial: predictive performance of competing-risks model in screening for pre-eclampsia at 35-37 weeks’ gestation. Ultrasound Obstet Gynecol 2022;59:69–75. 10.1002/uog.24789 PubMed DOI

Samplesize4Clinicaltrials: sample size calculation for the comparison of means or proportions in phase III clinical trials; Clinical trial design

Figueras F, Meler E, Iraola A, et al. . Customized birthweight standards for a Spanish population. Eur J Obstet Gynecol Reprod Biol 2008;136:20–4. 10.1016/j.ejogrb.2006.12.015 PubMed DOI

Gómez O, Figueras F, Fernández S, et al. . Reference ranges for uterine artery mean pulsatility index at 11-41 weeks of gestation. Ultrasound Obstet Gynecol 2008;32:128–32. 10.1002/uog.5315 PubMed DOI

Arduini D, Rizzo G. Normal values of pulsatility index from fetal vessels: a cross-sectional study on 1556 healthy fetuses. J Perinat Med 1990;18:165–72. 10.1515/jpme.1990.18.3.165 PubMed DOI

Kamath PS, Kim WR, Advanced Liver Disease Study Group . The model for end-stage liver disease (MELD). Hepatology 2007;45:797–805. 10.1002/hep.21563 PubMed DOI

Kellum JA. Acute kidney injury. Crit Care Med 2008;36(4 Suppl):S141–5. 10.1097/CCM.0b013e318168c4a4 PubMed DOI

Pfister RH, Bingham P, Edwards EM, et al. . The Vermont Oxford neonatal encephalopathy registry: rationale, methods, and initial results. BMC Pediatr 2012;12:84. 10.1186/1471-2431-12-84 PubMed DOI PMC

Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatric Critical Care Medicine 2005;6:2–8. 10.1097/01.PCC.0000149131.72248.E6 PubMed DOI

Spielberger CD. State-trait anxiety inventory. In: The Corsini Encyclopedia of Psychology. John Wiley & Sons Ltd, 2010: 1. 10.1002/9780470479216 DOI

Bech P, Olsen LR, Kjoller M, et al. . Measuring well-being rather than the absence of distress symptoms: a comparison of the SF-36 mental health subscale and the WHO-five well-being scale. Int J Methods Psychiatr Res 2003;12:85–91. 10.1002/mpr.145 PubMed DOI PMC

Hodnett ED, Simmons-Tropea DA. The labour agentry scale: psychometric properties of an instrument measuring control during childbirth. Res Nurs Health 1987;10:301–10. 10.1002/nur.4770100503 PubMed DOI

Stergiotou I, Bijnens B, Cruz-Lemini M, et al. . Maternal Subclinical vascular changes in fetal growth restriction with and without pre-Eclampsia - PubMed. Ultrasound Obstet Gynecol 2015;46:706–12. 10.1002/uog.14815 Available: https://pubmed.ncbi.nlm.nih.gov/25678131/ PubMed DOI

EMA . ICH E9 statistical principles for clinical trials - scientific guideline. European Medicines Agency; 2018. Available: https://www.ema.europa.eu/en/ich-e9-statistical-principles-clinical-trials-scientific-guideline [Accessed 3 Jan 2023].

EMA . Missing data in confirmatory clinical trials - scientific guideline. European Medicines Agency; 2018. Available: https://www.ema.europa.eu/en/missing-data-confirmatory-clinical-trials-scientific-guideline

See more in PubMed

ClinicalTrials.gov
NCT04766866